Palvella Therapeutics (PVLA) Consolidated Net Income (2013 - 2026)

Palvella Therapeutics (PVLA) has reported Consolidated Net Income for 14 consecutive years, with -$15.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Consolidated Net Income fell 92.63% year-over-year to -$15.8 million; the TTM figure through Mar 2026 stood at -$49.4 million (down 113.84% YoY), while the FY2025 annual figure was -$41.8 million, down 139.64% from the prior year.
• Consolidated Net Income declined to -$15.8 million in Q1 2026 per PVLA's latest filing, from -$12.8 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at $15.0 million in Q4 2023 and bottomed at -$16.0 million in Q1 2023.
• Historically, Consolidated Net Income has averaged -$7.8 million across 5 years, with a median of -$9.5 million in 2025.
• Annual changes were most pronounced in 2023 — Consolidated Net Income soared 221.65% — and 2024, when it sank 366.92%.
• Palvella Therapeutics' Consolidated Net Income stood at -$12.3 million in 2022, then jumped by 221.65% to $15.0 million in 2023, then plunged by 126.36% to -$4.0 million in 2024, then tumbled by 223.41% to -$12.8 million in 2025, then fell by 23.39% to -$15.8 million in 2026.
• Business Quant data shows PVLA's Consolidated Net Income at -$15.8 million in Q1 2026, -$12.8 million in Q4 2025, and -$11.3 million in Q3 2025.